Longitudinal Clinical Oncology NG Market Data indicates that the adoption of NGS for late-stage lung cancer has now surpassed 70% in the U.S., up from just 20% a decade ago. This statistical trend is a powerful indicator of the clinical acceptance of these tools. Data from 2024 also shows that the "Data Analysis" segment is growing 25% faster than the "Sequencing Hardware" segment, reflecting...